The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (19): 2806-2812.doi: 10.3969/j.issn.1006-5725.2024.19.024
• Reviews • Previous Articles
Weiwei CHEN,Ruolin PENG,Yi QU,Zhenyu. ZHANG()
Received:
2024-04-10
Online:
2024-10-10
Published:
2024-10-22
Contact:
Zhenyu. ZHANG
E-mail:zzy6565@sina.com
CLC Number:
Weiwei CHEN,Ruolin PENG,Yi QU,Zhenyu. ZHANG. Improvement and exploration of potassium⁃competitive acid blockers dual therapy for the eradication of Helicobacter pylori[J]. The Journal of Practical Medicine, 2024, 40(19): 2806-2812.
1 |
HOOI J K Y, LAI W Y, NG W K, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis [J]. Gastroenterology, 2017, 153(2): 420-429. doi:10.1053/j.gastro.2017.04.022
doi: 10.1053/j.gastro.2017.04.022 |
2 |
REN S, CAI P, LIU Y, et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis [J]. J Gastroenterol Hepatol, 2022, 37(3): 464-470. doi:10.1111/jgh.15751
doi: 10.1111/jgh.15751 |
3 | USUI Y, TANIYAMA Y, ENDO M, et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer [J]. N Engl J Med, 2023, 388(13): 1181-1190. |
4 | SUGIMOTO M, HIRA D, MURATA M, et al. Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy [J]. Antibiotics (Basel), 2020, 9(10): 645. |
5 | KAGAMI T, SAHARA S, ICHIKAWA H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype [J]. Aliment Pharmacol Ther, 2016, 43(10): 1048-1059. |
6 | HOSHINO S, KAWAMI N, TAKENOUCHI N, et al. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis [J]. Digestion, 2017, 95(2): 156-161. |
7 | TSUJIMAE M, YAMASHITA H, HASHIMURA H, et al. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori [J]. Digestion, 2016, 94(4): 240-246. |
8 | TANABE H, YOSHINO K, ANDO K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication [J]. Ann Clin Microbiol Antimicrob, 2018, 17(1): 29. |
9 | OZAKI H, HARADA S, TAKEUCHI T, et al. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy [J]. Digestion, 2018, 97(3): 212-218. |
10 |
GOTODA T, KUSANO C, SUZUKI S, et al. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naive cohort of junior high school students in Japan [J]. J Gastroenterol, 2020, 55(10): 969-976. doi:10.1007/s00535-020-01709-4
doi: 10.1007/s00535-020-01709-4 |
11 |
FURUTA T, YAMADE M, KAGAMI T, et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori [J]. Digestion, 2020, 101(6): 743-751. doi:10.1159/000502287
doi: 10.1159/000502287 |
12 | SUE S, KONDO M, SATO T, et al. Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: A single-arm, interventional study [J]. JGH Open, 2023, 7(1): 55-60. |
13 | HU Y, XU X, OUYANG Y B, et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study [J]. Helicobacter, 2022, 27(4): e12896. |
14 | LIN Y, XU H, YUN J, et al. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study [J]. Ann Transl Med, 2022, 10(18): 987. |
15 | SAKURAI Y, NISHIMURA A, KENNEDY G, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects [J]. Clin Transl Gastroenterol, 2015, 6(6): e94. |
16 |
YANG F, YU B, QIN L, et al. A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori [J]. Medicine (Baltimore), 2023, 102(41): e35610. doi:10.1097/md.0000000000035610
doi: 10.1097/md.0000000000035610 |
17 | QIAN H S, LI W J, DANG Y N, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy [J]. Am J Gastroenterol, 2023, 118(4): 627-634. |
18 | YAN T L, WANG J H, HE X J, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial [J]. Am J Gastroenterol, 2024,119(4):655-661. |
19 | HAN Y Y, ZHOU L, HU Y L, et al. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study [J]. J Gastroenterol, 2023, 58(12): 1167-1177. |
20 | PENG X, YAO J Y, MA Y Q, et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study [J]. Clin Gastroenterol Hepatol, 2024,22(6):1210-1216. |
21 | HU Y, XU X, LIU X S, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study [J]. Front Immunol, 2022, 13: 1049908. |
22 | PENG X, CHEN H W, WAN Y, et al. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study [J]. Clin Exp Med, 2023, 23(7): 4011-4019. |
23 | SU N Y, SHI Q, MEI H, et al. Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis [J]. Helicobacter, 2023, 28(5): e13003. |
24 | YU J, LV Y M, YANG P, et al. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection [J]. World J Gastroenterol, 2023, 29(20): 3133-3144. |
25 | GAO W, TENG G, WANG C, et al. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China [J]. Helicobacter, 2022, 27(5): e12918. |
26 |
ZUBERI B F, ALI F S, RASHEED T, et al. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial [J]. Pak J Med Sci, 2022, 38(4Part-II): 965-969. doi:10.12669/pjms.38.4.5436
doi: 10.12669/pjms.38.4.5436 |
27 | GAO W, XU Y, LIU J, et al. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies [J]. Helicobacter, 2023, 28(2): e12947. |
28 | GAO W, LIU J, WANG X, et al. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy [J]. Gut, 2024,73(9):1414-1420. |
29 |
SHAO Q Q, YU X C, YU M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial [J]. Helicobacter, 2022, 27(2): e12876. doi:10.1111/hel.12876
doi: 10.1111/hel.12876 |
30 | CHEY W D, MEGRAUD F, LAINE L, et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial [J]. Gastroenterology, 2022, 163(3): 608-619. |
31 | RATANA-AMORNPIN S, SANGLUTONG L, EIAMSITRAKOON T, et al. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan [J]. Helicobacter, 2023, 28(6): e13019. |
32 |
JENKINS H, SAKURAI Y, NISHIMURA A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects [J]. Aliment Pharmacol Ther, 2015, 41(7): 636-648. doi:10.1111/apt.13121
doi: 10.1111/apt.13121 |
33 | PENG X, CHENG L, YOU Y, et al. Oral microbiota in human systematic diseases [J]. Int J Oral Sci, 2022, 14(1): 14. |
34 |
JI Y, LIANG X, LU H. Analysis of by high-throughput sequencing: Helicobacter pylori infection and salivary microbiome [J]. BMC Oral Health, 2020, 20(1): 84. doi:10.1186/s12903-020-01070-1
doi: 10.1186/s12903-020-01070-1 |
35 | SUZUKI N, BEPPU R, YONEDA M, et al. Effects of eradication of Helicobacter pylori on oral malodor and the oral environment: a single-center observational study [J]. BMC Res Notes, 2020, 13(1): 406. |
36 | HU Y, XU X, OUYANG Y B, et al. Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication [J]. Helicobacter, 2022, 27(5): e12923. |
37 | PENG R, ZHANG Z, QU Y, et al. The impact of Helicobacter pylori eradication with vonoprazan-amoxicillin dual therapy combined with probiotics on oral microbiota: a randomized double-blind placebo-controlled trial [J]. Front Microbiol, 2023, 14: 1273709. |
38 | TRIFAN A, GIRLEANU I, COJOCARIU C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication [J]. World J Gastroenterol, 2013, 19(42): 7476-7479. |
39 | CHIBA M, TSUJI T, TAKAHASHI K, et al. Onset of Ulcerative Colitis after Helicobacter pylori Eradication Therapy: A Case Report [J]. Perm J, 2016, 20(2): e115-e118. |
40 | MURAD H A. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease? [J]. Acta Gastroenterol Belg, 2016, 79(3): 349-354. |
41 | LIOU J M, CHEN C C, CHANG C M, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial [J]. Lancet Infect Dis, 2019, 19(10): 1109-1120. |
42 |
HORII T, SUZUKI S, TAKANO C, et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication [J]. J Gastroenterol Hepatol, 2021, 36(12): 3314-3321. doi:10.1111/jgh.15572
doi: 10.1111/jgh.15572 |
43 | HU Y, XU X, OUYANG Y B, et al. Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication [J]. Front Cell Infect Microbiol, 2022, 12: 881968. |
44 | LEE K J, SON B K, KIM G H, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis [J]. Aliment Pharmacol Ther, 2019, 49(7): 864-872. |
45 | CHO Y K, CHOI M G, CHOI S C, et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer [J]. Aliment Pharmacol Ther, 2020, 52(5): 789-797. |
46 |
JUNG Y S, KIM S, KIM H Y, et al. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study [J]. Gut Liver, 2023,17(5):711-721. doi:10.5009/gnl220218
doi: 10.5009/gnl220218 |
47 | KIM J S, KO W, CHUNG J W, et al. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study [J]. Helicobacter, 2023, 28(3): e12977. |
48 |
LIU H N, WANG R, CAO Y, et al. Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan: A randomized, controlled, multicenter study [J]. Clin Transl Gastroenterol, 2024. doi:10.14309/ctg.0000000000000699
doi: 10.14309/ctg.0000000000000699 |
49 | KONG Q, MIRZA I A, ZHANG X, et al. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial [J]. Helicobacter, 2024, 29(3): e13098. |
50 |
JIANG Y, ZHANG R, FANG Y, et al. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis [J]. Therap Adv Gastroenterol, 2024, 17: 1-20. doi:10.1177/17562848241241223
doi: 10.1177/17562848241241223 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||